Cargando…

Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer

Inflammatory bowel disease (IBD) affects one million people in the US. Ulcerative colitis (UC) is a subtype of IBD that can lead to colitis-associated cancer (CAC). In UC, the rate of CAC is 3-5-fold greater than the rate of sporadic colorectal cancer (CRC). The pathogenesis of UC and CAC are due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Signs, Steven A., Fisher, Robert C., Tran, Uyen, Chakrabarti, Susmita, Sarvestani, Samaneh K., Xiang, Shao, Liska, David, Roche, Veronique, Lai, Wei, Gittleman, Haley R., Wessely, Oliver, Huang, Emina H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849194/
https://www.ncbi.nlm.nih.gov/pubmed/29560130
http://dx.doi.org/10.18632/oncotarget.24495
_version_ 1783306013941694464
author Signs, Steven A.
Fisher, Robert C.
Tran, Uyen
Chakrabarti, Susmita
Sarvestani, Samaneh K.
Xiang, Shao
Liska, David
Roche, Veronique
Lai, Wei
Gittleman, Haley R.
Wessely, Oliver
Huang, Emina H.
author_facet Signs, Steven A.
Fisher, Robert C.
Tran, Uyen
Chakrabarti, Susmita
Sarvestani, Samaneh K.
Xiang, Shao
Liska, David
Roche, Veronique
Lai, Wei
Gittleman, Haley R.
Wessely, Oliver
Huang, Emina H.
author_sort Signs, Steven A.
collection PubMed
description Inflammatory bowel disease (IBD) affects one million people in the US. Ulcerative colitis (UC) is a subtype of IBD that can lead to colitis-associated cancer (CAC). In UC, the rate of CAC is 3-5-fold greater than the rate of sporadic colorectal cancer (CRC). The pathogenesis of UC and CAC are due to aberrant interactions between host immune system and microenvironment, but precise mechanisms are still unknown. In colitis and CAC, microenvironmental fibroblasts exhibit an activated, inflammatory phenotype that contributes to tumorigenesis accompanied by excessive secretion of the chemokine CXCL8. However, mechanisms regulating CXCL8 secretion are unclear. Since it is known that miRNAs regulate chemokines such as CXCL8, we queried a microRNA library for mimics affecting CXCL8 secretion. Among the identified microRNAs, miR-20a/b was further investigated as its stromal expression levels inversely correlated with the amounts of CXCL8 secreted and predicted fibroblast tumor-promoting activity. Indeed, miR-20a directly bound to the 3′UTR of CXCL8 mRNA and regulated its expression by translational repression. In vivo co-inoculation studies with CRC stem cells demonstrated that fibroblasts characterized by high miR-20a expression had reduced tumor-promoting activities. These studies reveal that in stromal fibroblasts, miR-20a modulates CXCL8 function, therefore influencing tumor latency.
format Online
Article
Text
id pubmed-5849194
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58491942018-03-20 Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer Signs, Steven A. Fisher, Robert C. Tran, Uyen Chakrabarti, Susmita Sarvestani, Samaneh K. Xiang, Shao Liska, David Roche, Veronique Lai, Wei Gittleman, Haley R. Wessely, Oliver Huang, Emina H. Oncotarget Research Paper Inflammatory bowel disease (IBD) affects one million people in the US. Ulcerative colitis (UC) is a subtype of IBD that can lead to colitis-associated cancer (CAC). In UC, the rate of CAC is 3-5-fold greater than the rate of sporadic colorectal cancer (CRC). The pathogenesis of UC and CAC are due to aberrant interactions between host immune system and microenvironment, but precise mechanisms are still unknown. In colitis and CAC, microenvironmental fibroblasts exhibit an activated, inflammatory phenotype that contributes to tumorigenesis accompanied by excessive secretion of the chemokine CXCL8. However, mechanisms regulating CXCL8 secretion are unclear. Since it is known that miRNAs regulate chemokines such as CXCL8, we queried a microRNA library for mimics affecting CXCL8 secretion. Among the identified microRNAs, miR-20a/b was further investigated as its stromal expression levels inversely correlated with the amounts of CXCL8 secreted and predicted fibroblast tumor-promoting activity. Indeed, miR-20a directly bound to the 3′UTR of CXCL8 mRNA and regulated its expression by translational repression. In vivo co-inoculation studies with CRC stem cells demonstrated that fibroblasts characterized by high miR-20a expression had reduced tumor-promoting activities. These studies reveal that in stromal fibroblasts, miR-20a modulates CXCL8 function, therefore influencing tumor latency. Impact Journals LLC 2018-02-14 /pmc/articles/PMC5849194/ /pubmed/29560130 http://dx.doi.org/10.18632/oncotarget.24495 Text en Copyright: © 2018 Signs et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Signs, Steven A.
Fisher, Robert C.
Tran, Uyen
Chakrabarti, Susmita
Sarvestani, Samaneh K.
Xiang, Shao
Liska, David
Roche, Veronique
Lai, Wei
Gittleman, Haley R.
Wessely, Oliver
Huang, Emina H.
Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title_full Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title_fullStr Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title_full_unstemmed Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title_short Stromal miR-20a controls paracrine CXCL8 secretion in colitis and colon cancer
title_sort stromal mir-20a controls paracrine cxcl8 secretion in colitis and colon cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849194/
https://www.ncbi.nlm.nih.gov/pubmed/29560130
http://dx.doi.org/10.18632/oncotarget.24495
work_keys_str_mv AT signsstevena stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT fisherrobertc stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT tranuyen stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT chakrabartisusmita stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT sarvestanisamanehk stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT xiangshao stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT liskadavid stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT rocheveronique stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT laiwei stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT gittlemanhaleyr stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT wesselyoliver stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer
AT huangeminah stromalmir20acontrolsparacrinecxcl8secretionincolitisandcoloncancer